Understanding Huntington's Disease

Researchers are inching ever closer to a treatment for the inherited neurodegenerative disorder Huntington's disease (HD). Following close on the heels of recent optimistic reports on fetal cell implants1,2 comes a report from Johns Hopkins University that sheds light on a possible mechanism of neuronal destruction in HD.3 The work reveals possible new drug targets. Legendary folksinger Woody Guthrie's fight with HD brought the disease into the public eye in the 1960s. Today, some 30,000 peopl

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Legendary folksinger Woody Guthrie's fight with HD brought the disease into the public eye in the 1960s. Today, some 30,000 people in the United States are affected by the late-onset, autosomal dominant condition. Early symptoms--such as anger or depression, repetitive fidgety movements, and a clumsiness and tendency to fall--may go unnoticed for years. Neurological deterioration, reflecting cell death in the brain's striatum, typically continues for 15 to 20 years. HD has left its mark on the recent history of genetics, but has remained frustratingly untreatable. Discovery of a marker in 1983,4 and of the gene in 1993,5 gave affected families the option of predictive testing, but without any treatments that could halt or even slow the disease process.

As one of the first "triplet repeat" disorders to be described, HD is also one of eight "polygln" disorders in which an expanded repeat of the RNA triplet CAG adds extra glutamines ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ricki Lewis

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo